Brokers Issue Forecasts for Vigil Neuroscience, Inc.’s Q1 2024 Earnings (NASDAQ:VIGL)

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – HC Wainwright issued their Q1 2024 EPS estimates for shares of Vigil Neuroscience in a report released on Wednesday, March 27th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.58) per share for the quarter. HC Wainwright has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.56) per share. HC Wainwright also issued estimates for Vigil Neuroscience’s Q3 2024 earnings at ($0.58) EPS.

Separately, Morgan Stanley lowered shares of Vigil Neuroscience from an “equal weight” rating to an “underweight” rating and reduced their target price for the company from $13.00 to $4.00 in a research note on Tuesday, December 19th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.40.

Vigil Neuroscience Stock Up 14.7 %

Vigil Neuroscience stock opened at $3.20 on Thursday. The firm has a 50-day moving average price of $3.06 and a two-hundred day moving average price of $4.32. The firm has a market capitalization of $114.82 million, a price-to-earnings ratio of -1.50 and a beta of 1.80. Vigil Neuroscience has a 52-week low of $2.53 and a 52-week high of $11.11.

Institutional Trading of Vigil Neuroscience

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp raised its position in shares of Vigil Neuroscience by 16.3% during the 3rd quarter. State Street Corp now owns 21,374 shares of the company’s stock worth $195,000 after buying an additional 3,000 shares in the last quarter. Royal Bank of Canada bought a new stake in shares of Vigil Neuroscience in the 2nd quarter worth approximately $33,000. Barclays PLC raised its holdings in shares of Vigil Neuroscience by 3.7% in the 4th quarter. Barclays PLC now owns 105,893 shares of the company’s stock worth $1,324,000 after purchasing an additional 3,730 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Vigil Neuroscience by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 799,197 shares of the company’s stock worth $2,701,000 after purchasing an additional 5,231 shares in the last quarter. Finally, California State Teachers Retirement System bought a new stake in shares of Vigil Neuroscience in the 2nd quarter worth approximately $50,000. 83.64% of the stock is currently owned by institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.